Disease/Infection News

RSS

Seriously ill children administered zinc in addition to antibiotics respond better, more quickly to treatment, study shows

"In a newly released clinical study, conducted in India" and published in the Lancet on Thursday, "hundreds of seriously ill infants who received zinc -- an essential micronutrient for the immune system and human growth -- as well as antibiotics, responded better and more quickly to treatment than those who did not," IRIN reports.

1 Jun 2012

Foreign-born populations in the U.S. are at increased risk for chronic HBV

The prevalence of chronic hepatitis B virus (HBV) infection in the U.S. may be as high as 2.2 million cases according to a new study now available in Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

1 Jun 2012

Scientists discover SL9266 'switch' in the Hepatitis C virus

Scientists have discovered a 'switch' in the Hepatitis C virus which could be used as a target for new kinds of drug treatment.

1 Jun 2012

Einstein receives NIH grant to create new vaccine against TB

The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered Mycobacterium smegmatis, which is closely related to the bacterial species (Mycobacterium tuberculosis) that causes TB in humans.

1 Jun 2012

Illumina launches Nextera XT DNA Sample Preparation Kits

Illumina today introduced the Nextera XT DNA Sample Preparation Kit, the easiest way for researchers to prepare and sequence small genomes, PCR amplicons, and plasmids.

From Illumina, Inc. 1 Jun 2012

New photoactive compound eradicates 'Iraqibacter' from wounds and skin infections

Researchers at the University of California, Santa Cruz, have developed a novel approach for eradicating drug-resistant bacteria from wounds and skin infections, using light to trigger the controlled release of nitric oxide. The UCSC team developed a photoactive compound that releases nitric oxide when exposed to light, and loaded it into a porous, biocompatible material that could be applied as a sprayable powder.

31 May 2012

Every Child Deserves a 5th Birthday weekly theme is PMTCT

"The Every Child Deserves a 5th Birthday theme for this week is prevention of mother-to-child transmission of HIV (PMTCT)," an e-mail alert from USAID reports, noting, "PMTCT provides HIV prevention, treatment, care, and support services for the whole family and is the most effective way to create an HIV-free generation."

31 May 2012

Aeras, IDRI partner to develop novel TB vaccine

In a guest post on the Global Health Technologies Coalition's "Breakthroughs" blog, Jamie Elizabeth Rosen, media and communications manager at Aeras, interviews Steven Reed, founder, president, and chief scientific officer of the Infectious Disease Research Institute (IDRI), "a 120-person non-profit biotech committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty."

31 May 2012

Implications of eradicating polio, or failing to do so, go beyond public health

In this Atlantic opinion piece, Rachel Hills, a freelance writer based in London, examines the WHO's decision on May 25 to declare polio a public health emergency, "calling for the 194 member states to fully fund the Global Polio Eradication Initiative, and fill the currently $945 million gap in its budget for 2012-13."

31 May 2012

Simple soft-drink cooler could help patients battle antibiotic-resistant TB

Tuberculosis, now largely controlled in the industrialized world, remains a stubbornly persistent killer in most of Africa, as well as parts of Asia and South America. The spread of multidrug-resistant strains of TB has slowed progress against the devastating disease, which is estimated to strike more than 10 million people annually. Now a modified soft-drink cooler, developed by researchers at MIT's D-Lab, could make a dent in the disease's impact.

31 May 2012

CIA's use of health workers in intelligence operations could hurt 'innocent people'

"The CIA's vaccination gambit put at risk something very precious -- the integrity of public health programs in Pakistan and around the globe" and has "also added to the dangers facing nongovernmental organizations (NGOs) in a world that's increasingly hostile to U.S. aid organizations," opinion writer David Ignatius writes in a Washington Post opinion piece.

31 May 2012

Clorox Healthcare to be showcased at APIC 2012 conference

Clorox Professional Products Company, a division of The Clorox Company, will showcase Clorox Healthcare, its new strengthened comprehensive product offerings and educational initiatives to meet healthcare professionals' diverse needs, at the Association for Professionals in Infection Control and Epidemiology (APIC) 2012 Conference in San Antonio, Texas, June 4-6.

31 May 2012

Wellmune minimizes risk of URTI among marathoners

Marathoners taking Wellmune WGP, a natural immune health ingredient, for four weeks experienced an average reduction of 40% in upper respiratory tract infection symptomatic days that commonly afflict long-distance runners, according to new clinical study results presented today at the American College of Sports Medicine 59th annual meeting.

31 May 2012

Trade officials at WIPO fail to make progress on proposals to improve access to generic medicines

Trade officials met last week at the U.N. World Intellectual Property Organization "to make progress on a proposal that would allow poor countries to provide inexpensive generic versions of lifesaving medications, rather than rely a single version of the same drugs under expensive patent monopolies," but the U.S. "remained steadfast in rejecting proposals aimed at lowering the prices of existing medicines in poor countries," the Huffington Post reports.

31 May 2012

Top-line results from Alnylam’s ALN-RSV01 Phase IIb trial on RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today top-line results from a Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection in lung transplant patients.

31 May 2012

Researchers identify mechanism key in drug allergy

Adverse drug reactions are a major issue that cause harm, are costly and restrict treatment options for patients and the development of new drugs. A groundbreaking finding by researchers from the La Jolla Institute for Allergy & Immunology could lead to a new way to dramatically improve drug safety by identifying drugs at risk to cause potentially fatal genetic-linked hypersensitivity reactions before their use in man.

30 May 2012

GPUs simulate molecular processes during swine flu drug treatment

Professor Adrian Mulholland and Dr Christopher Woods from Bristol's School of Chemistry, together with colleagues in Thailand, used graphics processing units (GPUs) to simulate the molecular processes that take place when these drugs are used to treat the H1N1-2009 strain of influenza - commonly known as 'swine flu'.

30 May 2012

Genetic analysis on Korean mummy reveals unique HBV genotype C2 sequence

The discovery of a mummified Korean child with relatively preserved organs enabled an Israeli-South Korean scientific team to conduct a genetic analysis on a liver biopsy which revealed a unique hepatitis B virus (HBV) genotype C2 sequence common in Southeast Asia.

30 May 2012

Nature Genetics publishes results from whole genome-wide study of recurrent HBV integration in HCC

The Asian Cancer Research Group (ACRG)—an independent, not-for-profit company established by Eli Lilly and Company, Merck (known as MSD outside the United States and Canada) and Pfizer Inc.—in collaboration with BGI—the world's largest genomics organization—today announced the publication of results from a whole genome-wide study of recurrent hepatitis B virus (HBV) integration in hepatocellular carcinoma (HCC) in Nature Genetics.

30 May 2012

Scientists solve 50-year mystery behind cholera

For 50 years scientists have been unsure how the bacteria that gives humans cholera manages to resist one of our basic innate immune responses. That mystery has now been solved, thanks to research from biologists at The University of Texas at Austin.

30 May 2012